Latest Conference Coverage

NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy

The professor of neurology and pediatrics at the University of Rochester Medical Center provided insight on the emerging therapies and advancements for treating patients with Duchenne muscular dystrophy.

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

New Treatments for Duchenne Muscular Dystrophy: Emma Ciafaloni, MD The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the new and future treatments for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]

Virtual Reality Training May Improve Quality of Care in Lower Limb Spasticity With OnabotulinumtoxinA

Results from pilot program using a VR-based platform suggest medical trainees may benefit from further VR training to gain a complete baseline knowledge of treating lower limb spasticity with onabotulinumtoxinA.

Tele-Yoga Breathing for Respiratory Function Proves Feasibility in Amyotrophic Lateral Sclerosis

A nonrandomized pilot study demonstrated high adherence rates and acceptability ratings with tele-yoga breathing in patients with ALS, proving that it is a safe and feasible practice.

Vaccinated Individuals With Myasthenia Gravis With COVID-19 Infection are More at Health Risk

Adults with myasthenia gravis who contracted COVID-19 were at twice the risk of hospitalization, ICU admission, and death based on data from a recent population-based study.

Evaluating the Treatment Evolution of Myasthenia Gravis and Use of Immunosuppressants: Nicholas Silvestri, MD, FAAN

The clinical professor of neurology at the University at Buffalo provided insight on the advances in treatment options for patients with myasthenia gravis over the past few decades. [WATCH TIME: 3 minutes]

Patients Receiving Efgartigimod Respond to COVID-19 Vaccination With IgG Antibodies

In an investigation on the effect of treatment with efgartigimod on humoral immune responses to COVID-19 vaccination, the immunization resulted in antigen-specific IgG responses in most patients.

Understanding New Guidelines to Improve Management of Painful Diabetic Neuropathies

Brian Callaghan, MD, MS, associate professor at the University of Michigan, discussed his presentation at AANEM 2022 on changing the treatment paradigm for painful diabetic neuropathies.

NeurologyLive® Brain Games: September 25, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Repetitive Nerve Stimulation Exhibits Positive Association with Inpatient Diagnosis of Myasthenia Gravis

Findings from retrospective study show that repetitive nerve stimulation is a highly sensitive and specific test for the diagnosis of myasthenia gravis in an inpatient setting, with its results being more rapidly available in comparison with antibody testing.

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]

Substantial Economic Burden Is Frequent in Myasthenia Gravis, Primarily Driven by Direct Costs

Among a surveyed cohort of patients with myasthenia gravis, 75% reported that their work was impacted, and 27% of respondents claimed they lost wages as a result of MG.

Eplontersin Treatment Results in Reduction in Serum Transthyretin in Amyloidosis

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

Rozanolixizumab Continues to Show Efficacy, High Responder Rates in Myasthenia Gravis

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.

CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]

Pooled Clinical Trial Data Suggests Antidrug Antibody Testing for Alglucosidase Alfa-Exposed Patients With Pompe Disease

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.

ADAPT/ADAPT+ Study Show Improvements in Myasthenia Gravis Efficacy Scales With Efgartigimod

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.

Changing the Treatment of Diabetic and Inflammatory Neuropathies: Brian Callaghan, MD, MS

The associate professor at the University of Michigan provided insight on new guidelines to treat painful diabetic neuropathy. [WATCH TIME: 2 minutes]

Givosiran Shows Long-Term Clinical Benefit in Acute Hepatic Porphyria, Open-Label Findings Suggest

Potential Temporal Association Found Between Guillain-Barré Syndrome and COVID-19 Vaccination in Pediatrics

From the pre-COVID period to 6 weeks after vaccination, the reporting rate of GBS was significantly different, regardless of whether Brighton criteria was applied to the analysis. The authors noted that passive surveillance limitations warrant further analysis.

CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis

Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.

Design of Phase 3 URSA Study of Tolebrutinib in Myasthenia Gravis Detailed

The phase 3 study, paused at US sites by the FDA, seeks to enroll 154 individuals with generalized myasthenia gravis, both seropositive and seronegative.

High Proportion of Zilucoplan Responders Identified in Secondary Analysis of RAISE Trial

After 12 weeks of treatment with zilucoplan 0.3 mg/kg, almost three-fourths of patients demonstrated at least a 3-point reduction in Myasthenia Gravis Activities of Daily Living scores.

Cipaglucosidase Alfa/Miglustat Shows Beneficial Treatment Effects for Patients With Late-onset Pompe Disease

Most ambulatory patients had improved pulmonary functions and biomarker outcomes with cipaglucosidase alfa/miglustat that were sustained through a less than 36-month follow-up period.

Endovascular Therapy Shows Better Functional Outcomes for Acute Stroke

Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

A study presented at the MDS Congress 2022 found an association between migraine and the incidence of Parkinson disease in the middle-aged and older population.

IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

Results from a pooled analysis extend and support the safety and the tolerability of the use of incobotulinumtoxinA for the treatment of adults with neurological disorders.

Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.

Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

The Parkinson disease agent showed a safe and tolerable profile, with significantly greater improvements in MDS-UPDRS-III scores and OFF time per day.

NeurologyLive® Brain Games: September 18, 2022